Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 3/20 | 0.48 |
| ▸ | HTR1A | P08908 | 3/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.48 |
| ▸ | TACR2 | P21452 | 2/20 | 0.48 |
| ▸ | TACR1 | P25103 | 2/20 | 0.48 |
| ▸ | EED | O75530 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MLNR | O43193 | 1/20 | 0.48 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HLA-A | P04439 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6039981 | 0.84 | OPRM1 (0.48) | HTR1ASLC6A4OPRM1SIGMAR1 | |
| SCHEMBL6039528 | 0.84 | HRH1 (0.47) | HRH1HTR1ASLC6A4TACR2TACR1 | |
| SCHEMBL6362136 | 0.84 | OPRM1 (0.43) | HTR1ASLC6A4MEN1USP2LMNA | |
| SCHEMBL6039497 | 0.83 | PRCP (0.52) | MEN1CYP1A2CYP3A4DRD2DRD4 | |
| SCHEMBL6039830 | 0.83 | HTR1A (0.49) | HTR1ASLC6A4GAADRD2DRD4 | |
| SCHEMBL6039970 | 0.83 | SIGMAR1 (0.47) | HTR1ASLC6A4KCNH2GAADRD2 | |
| SCHEMBL6039470 | 0.81 | PRCP (0.47) | HRH1KCNH2MEN1LMNATP53 | |
| SCHEMBL6039802 | 0.80 | PRCP (0.57) | KCNH2MEN1TP53CYP1A2CYP3A4 | |
| SCHEMBL6365086 | 0.77 | HTR2C (0.47) | LMNATP53CYP1A2FYNCYP3A4 | |
| SCHEMBL6039514 | 0.77 | HTR1A (0.43) | HTR1ASLC6A4SIGMAR1HRH3IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664042-A1 | IMIDAZO 1,5-a PYRIDINE OR IMIDAZO 1,5-a PIPERIDINE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF MEDICAMENT AGAINST 5-HT2A RECEPTOR-RELATED DISORDERS | Galapagos N.V. (BE) | 2006-06-07 | — | — | EP | claimed |
| US-20050215555-A1 | Imidazo[1,5-a]pyridine serotonin (5-HT) 5-HT2A receptor antagonists such as 1-phenyl-3-[1-(2-phenylethyl)piperidin-4-yl]imidazo[1,5-a]pyridine; psychological disorders, sleep disorders, addiction, cardiovascular disorders, epilepsy, glaucoma | BLOVITRUM AB (SE) | 2005-09-29 | — | — | US | claimed |
| WO-2005021545-A1 | IMIDAZO[1,5-a]PYRIDINE OR IMIDAZO[1,5-a]PIPERIDINE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF MEDICAMENT AGAINST 5-HT2A RECEPTOR-RELATED DISORDERS | GALAPAGOS NV (BE) | 2005-03-10 | — | — | WO | claimed |
| EP-1664042-A1 | IMIDAZO 1,5-a PYRIDINE OR IMIDAZO 1,5-a PIPERIDINE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF MEDICAMENT AGAINST 5-HT2A RECEPTOR-RELATED DISORDERS | Galapagos N.V. (BE) | 2006-06-07 | — | — | EP | disclosed |
| US-20050215555-A1 | Imidazo[1,5-a]pyridine serotonin (5-HT) 5-HT2A receptor antagonists such as 1-phenyl-3-[1-(2-phenylethyl)piperidin-4-yl]imidazo[1,5-a]pyridine; psychological disorders, sleep disorders, addiction, cardiovascular disorders, epilepsy, glaucoma | BLOVITRUM AB (SE) | 2005-09-29 | — | — | US | disclosed |
| WO-2005021545-A1 | IMIDAZO[1,5-a]PYRIDINE OR IMIDAZO[1,5-a]PIPERIDINE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF MEDICAMENT AGAINST 5-HT2A RECEPTOR-RELATED DISORDERS | GALAPAGOS NV (BE) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215555-A1 | Imidazo[1,5-a]pyridine serotonin (5-HT) 5-HT2A receptor antagonists such as 1-phenyl-3-[1-(2-phenylethyl)piperidin-4-yl]imidazo[1,5-a]pyridine; psychological disorders, sleep disorders, addiction, cardiovascular disorders, epilepsy, glaucoma | HTR1A, HTR2A, HTR5A | HRH1 351/4885HTR1A 1/4885SLC6A4 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.